MiR-23b represents a novel therapeutic approach for clinical treatment of sepsis-induced cardiomyopathy via targeting myeloid differentiation factor 88 (MyD88) mediated with NF-κB signaling pathway [16]. This evidence concerns the gene NFKB1 and Sepsis.